Maine State Library

Digital Maine
Attorney General Consumer Division Formal
Actions

Attorney General

March 2022

FTC & State of Maine v Health Research Labs & Kramer Duhon Stipulated Final Judgment & Order

Follow this and additional works at: https://digitalmaine.com/ag_consumer_division_formal_actions

Recommended Citation
"FTC & State of Maine v Health Research Labs & Kramer Duhon - Stipulated Final Judgment & Order"
(2022). Attorney General Consumer Division Formal Actions. 296.
https://digitalmaine.com/ag_consumer_division_formal_actions/296

This Article is brought to you for free and open access by the Attorney General at Digital Maine. It has been
accepted for inclusion in Attorney General Consumer Division Formal Actions by an authorized administrator of
Digital Maine. For more information, please contact statedocs@maine.gov.

Case 2:17-cv-00467-JDL Document 15 Filed 01/16/18 Page 1 of 33

PagelD #: 138

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MAINE

)
FEDERAL TRADE COMMISSION and
STATE OF MAINE,

)
)

) Case No. 2:17-CV-00467-JDL
Plaintiffs,

)
)

v.

) STIPULATED FINAL JUDGMENT

) AND ORDER FO R PERMANENT
) INJUNCTION AND OTHER
) EQUITABLE R ELIEF
)
KRAMER DUHON, individually and as an owner )
and officer of HEALTH RESEARCH
)
LABORATORIES, LLC,
)
HEALTH RESEARCH LABORATORIES, LLC,
a limited liability company, and

)
Defendants.

)

________________________________________________ )

Plaintiffs, the Federal Trade Commission (“FTC” or “Commission”) and the State of
Maine, as represented in this matter by the Office of the Attorney General of Maine (“Maine
AG”) (collectively, “Plaintiffs”), filed a Complaint for Permanent Injunction and Other Equitable
Relief against Defendants pursuant to Section 13(b) of the Federal Trade Commission Act (“FTC
Act”), 15 U.S.C. § 53(b), pursuant to Section 4(a) o f the Telemarketing and Consumer Fraud and
Abuse Prevention Act (“Telemarketing Act”), 15 U.S.C. § 6103(a), and pursuant to Section 209
of the Maine Unfair Trade Practices Act (“Maine UTPA”), 5 M.R.S.A. § 209, to obtain
permanent injunctive relief, rescission or reformation of contracts, restitution, the refund of
monies paid, disgorgement of ill-gotten monies, and other equitable relief for Defendants’ acts or
practices in violation of Sections 5(a) and 12 of the FTC Act, 15 U.S.C. §§ 45(a) and 52, the
Telemarketing Act, 15 U.S.C. §§ 6101-6108, the FTC’s Trade Regulation Rule entitled
“Telemarketing Sales Rule” (“TSR”), 16 C.F.R. Part 310, the Electronic Fund Transfer Act
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(“EFTA”), 15 U.S.C. §§ 1693-1693i% and its implementing Regulation E, 12 C.F.R. § 1005.10,
and Section 207 of the Maine UTPA, 5 M.R.S.A. § 207, in connection with the labeling,
advertising, marketing, distribution, and sale of products purported to cause weight loss, treat
arthritis and relieve joint and back pain, and prevent or mitigate cognitive decline.
The Commission, the State of Maine, and Defendants Health Research Laboratories, LLC
and Kramer Duhon (hereafter collectively, “Defendants”), stipulate to the entry o f this Final
Judgment and Order for Permanent Injunction and Other Equitable Relief to resolve all matters
in dispute in this action between them, including the allegations in the Complaint.
FINDINGS
1.

This Court has jurisdiction over this matter.

2.

The Complaint charges that Defendants participated in deceptive acts or practices

in violation of Sections 5(a) and 12 of the FTC Act, 15 U.S.C. §§ 45(a) and 52, the
Telemarketing Act, 15 U.S.C. §§ 6101-6108, the TSR, 16C.F.R. Part 310, the EFTA, 15 U.S.C.
§§ 1693-1693r, and its implementing Regulation E, 12 C.F.R. § 1005.10, and Section 207 of the
Maine UTPA, 5 M.R.S.A. § 207, in connection with the labeling, advertising, marketing,
distribution, and sale of products purported to cause weight loss, treat arthritis and relieve joint
and back pain, and prevent or mitigate cognitive decline.
3.

Defendants neither admit nor deny any of the allegations in the Complaint, except

as specifically stated in this Order. Defendants admit the facts necessary to establish jurisdiction
only for purposes of this action.
4.

Defendants waive any claim that they may have under the Equal Access to Justice

Act, 28 U.S.C. § 2412, concerning the prosecution of this action through the date of this Order.
The parties agree to bear their own costs and attorney fees.
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Defendants and Plaintiffs waive all rights to appeal or otherwise challenge or

contest the validity of this Order.
DEFINITIONS
For the purpose of this Order, the following definitions apply:
1.

“Charge” or “C harged” means any attempt to collect money or other

consideration from a consumer, including but not limited to causing billing information to be
submitted for payment, including against the consumer’s credit card, debit card, bank account,
telephone bill, or other account.
2.

“Clear(ly) and Conspicuous(ly)” means that a required disclosure is difficult to

miss (le., easily noticeable) and easily understandable by ordinary consumers, including in all of
the following ways:
A.

In any communication that is solely visual or solely audible, the disclosure

must be made through the same means through which the communication is presented. In any
communication made through both visual and audible means, such as a television advertisement,
the disclosure must be presented simultaneously in both the visual and audible portions of the
communication even if the representation requiring the disclosure is made in only one means;
B.

A visual disclosure, by its size, contrast, location, the length of time it

appears, and other characteristics, must stand out from any accompanying text or other visual
elements so that it is easily noticed, read, and understood;
C.

An audible disclosure, including by telephone or streaming video, must be

delivered in a volume, speed, and cadence sufficient for ordinary consumers to easily hear and
understand it;
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In any communication using an interactive electronic medium, such as the

Internet or software, the disclosure must be unavoidable;
E.

The disclosure must use diction and syntax understandable to ordinaiy

consumers and must appear in each language in which the representation that requires the
disclosure appears;
F.

The disclosure must comply with these requirements in each medium

through which it is received, including all electronic devices and face-to-face communications;
G.

The disclosure must not be contradicted or mitigated by, or inconsistent

with, anything else in the communication; and
H.

When the representation or sales practice targets a specific audience, such

as children, the elderly, or the terminally ill, “ordinary consumers” includes reasonable members
of that group.
3.

“Close Proximity” means that the disclosure is very near the triggering

representation. For example, a disclosure made through a hyperlink, pop-up, interstitial, or other
similar technique is not in close proximity to the triggering representation.
4.

“C orporate Defendant” means Health Research Laboratories, LLC, and its

successors and assigns.
5.

“Covered Product” means any Dietary Supplement, Food, or Drug, including

BioTherapex and NeuroPlus.
6.

“Defendants” means the Individual Defendant and the Corporate Defendant,

individually, collectively, or in any combination.
7.

“Dietary Supplement” means: (1) any product labeled as a dietary supplement

or otherwise represented as a dietary supplement; or (2) any pill, tablet, capsule, powder, softgel,
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gelcap, liquid, or other similar form containing one or more ingredients that are a vitamin,
mineral, herb or other botanical, amino acid, probiotic, or other dietary substance for use by
humans to supplement the diet by increasing the total dietary intake, or a concentrate, metabolite,
constituent, extract, or combination of any ingredient described above, that is intended to be
ingested, and is not represented to be used as a conventional food or as a sole item of a meal or
the diet.
8.

“Drug” means: (1) articles recognized in the official United States

Pharmacopoeia, official Homoeopathic Pharmacopoeia of the United States, or official National
Formulary, or any supplement to any of them; (2) articles intended for use in the diagnosis, cure,
mitigation, treatment, or prevention of disease in humans or other animals; (3) articles (other
than food) intended to affect the structure or any function of the body of humans or other
animals; and (4) articles intended for use as a component of any article specified in (1), (2), or
(3); but does not include devices or their components, parts, or accessories.
9.

“Essentially Equivalent Product” means a product that contains the identical

ingredients, except for inactive ingredients (e . g binders, colors, fillers, excipients), in the same
form and dosage, and with the same route of administration (e.g., orally, sublingually), as the
Covered Product; provided that the Covered Product may contain additional ingredients if
reliable scientific evidence generally accepted by experts in the field indicates that the amount
and combination of additional ingredients is unlikely to impede or inhibit the effectiveness of the
ingredients in the Essentially Equivalent Product.
10.

“Food” means: (1) any article used for food or drink for humans or other

animals; (2) chewing gum; and (3) any article used for components of any such article.
11.

“Including” means including but not limited to.
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12.

“Individual Defendant” means Kramer Duhon.

13.

“Negative Option Feature” means, in an offer or agreement to sell or provide

any good, program, or service, a provision under which the consumer's silence or failure to take
an affirmative action to reject a good, program, or service, or to cancel the agreement, is
interpreted by the seller or provider as acceptance or continuing acceptance of the offer.
14.

“Person” means a natural person, an organization, or other legal entity, including

a corporation, partnership, sole proprietorship, limited liability company, association,
cooperative, or any other group or combination acting as an entity.
15.

“Preauthorized Electronic Fund Transfer” as defined by the Electronic Fund

Transfer Act, 15 U.S.C. § 1693a(10), means an electronic fund transfer authorized in advance to
recur at substantially regular intervals.
I.

BANNED WEIGHT-LOSS CLAIMS
IT IS HEREBY ORDERED that Defendants, Defendants' officers, agents, employees,
and all other persons in active concert or participation with any of them, who receive actual
notice of this Order, whether acting directly or indirectly, in connection with the manufacturing,
labeling, advertising, promotion, offering for sale, sale, or distribution of any Dietary
Supplement, over-the-counter Drug, patch, cream, wrap, or other product worn on the body or
rubbed into the skin, are permanently restrained and enjoined from representing, or assisting
others in representing, in any manner, expressly or by implication, including through the use of a
product name, endorsement, depiction, illustration, trademark, or trade name, that such product:
A.

Causes weight loss of two pounds or more a week for a month or more without
dieting or exercise;
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B.

Causes substantial weight loss no matter what or how much the consumer eats;

C.

Causes permanent weight loss;

D.

Blocks the absorption of fat or calories to enable consumers to lose substantial
weight;

E.

Safely enables consumers to lose more than three pounds per week for more than
four weeks;

F.

Causes substantial weight loss for all users; or

G.

Causes substantial weight loss by wearing a product on the body or rubbing it into
the skin.
II.

PROHIBITED REPRESENTATIONS: OTHER WEIGHT-LOSS CLAIMS, JOIN TRELATED DISEASE CLAIMS, AND A LZH EIM ER’S DISEASE, MEMORY, AND
COGNITIVE PERFORMANCE CLAIMS
IT IS FURTHER ORDERED that Defendants, Defendants' officers, agents, employees,
and all other persons in active concert or participation with any of them, who receive actual
notice of this Order, whether acting directly or indirectly, in connection with the manufacturing,
labeling, advertising, promotion, offering for sale, sale, or distribution of any Covered Product,
are permanently restrained and enjoined from making, or assisting others in making, expressly or
by implication, including through the use of a product name, endorsement, depiction, or
illustration, any representation, other than representations covered under the Section of this
Order entitled Banned Weight-Loss Claims, that, in humans, such product:
A.

Causes or assists in causing weight loss, including any specific amount of weight
loss;

B.

Causes or assists in causing fat loss, including any specific amount of fat loss;
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C.

Treats or cures rheumatism, arthritis, or osteoarthritis;

D.

Relieves joint pain, back pain, or muscle pain;

E.

Protects the brain against Alzheimer’s disease or dementia;

F.

Reverses memory loss;

G.

Improves memory, concentration, or cognitive performance; or

H.

Cures, mitigates, or treats any disease,
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unless the representation is non-misleading and, at the time of making such representation, they
possess and rely upon competent and reliable scientific evidence substantiating that the
representation is true. For purposes of this Section, competent and reliable scientific evidence
shall consist of human clinical testing of the Covered Product, or of an Essentially Equivalent
Product, that is sufficient in quality and quantity based on standards generally accepted by
experts in the relevant disease, condition, or function to which the representation relates, when
considered in light of the entire body of relevant and reliable scientific evidence, to substantiate
that the representation is true. Such testing must be: (1) randomized, double-blind, and placebocontrolled; and (2) conducted by researchers qualified by training and experience to conduct
such testing. In addition, all underlying or supporting data and documents generally accepted by
experts in the field as relevant to an assessment of such testing as described in the Section
entitled Preservation of Records Relating to Competent and Reliable Human Clinical Tests or
Studies must be available for inspection and production to Plaintiffs. Persons covered by this
Section have the burden of proving that a product satisfies the definition of Essentially
Equivalent Product.
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III.
PROHIBITED REPRESENTATIONS: OTHER HEALTH-RELATED CLAIMS
IT IS FURTHER ORDERED that Defendants, Defendants’ officers, agents, and
employees, and all other persons in active concert or participation with any of them, who receive
actual notice of this Order, whether acting directly or indirectly, in connection with the
manufacturing, labeling, advertising, promotion, offering for sale, sale, or distribution of any
Covered Product, are permanently restrained and enjoined from making, or assisting others in
making, expressly or by implication, including through the use of a product name, endorsement,
depiction, or illustration, any representation about the health benefits, safety, performance, or
efficacy of any Covered Product, other than representations covered under the Sections of this
Order entitled Banned Weight-Loss Claims and Prohibited Representations: Other Weight-Loss
Claims, Joint-Related Disease Claims, and Alzheimer’s Disease, Memory, and Cognitive
Performance Claims, unless the representation is non-misleading, and, at the time of making
such representation, they possess and rely upon competent and reliable scientific evidence that is
sufficient in quality and quantity based on standards generally accepted by experts in the relevant
disease, condition, or function to which the representation relates, when considered in light of the
entire body of relevant and reliable scientific evidence, to substantiate that the representation is
true.
For purposes of this Section, competent and reliable scientific evidence means tests,
analyses, research, or studies (1) that have been conducted and evaluated in an objective manner
by experts in the relevant disease, condition, or function to which the representation relates;
(2) that are generally accepted by such experts to yield accurate and reliable results; and (3) that
are randomized, double-blind, and placebo-controlled human clinical testing of the Covered
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Product, or of an Essentially Equivalent Product, when such experts would generally require
such human clinical testing to substantiate that the representation is true. In addition, when such
tests or studies are human clinical tests or studies, all underlying or supporting data and
documents generally accepted by experts in the field as relevant to an assessment of such testing
as set forth in the Section entitled Preservation of Records Relating to Competent and Reliable
Human Clinical Tests or Studies must be available for inspection and production to Plaintiffs.
Persons covered by this Section have the burden of proving that a product satisfies the definition
of Essentially Equivalent Product.
IV,
PROHIBITED REPRESENTATIONS REGARDING TESTS, STUDIES,
OR O TH ER RESEARCH
IT IS FURTHER ORDERED that Defendants, Defendants’ officers, agents, employees,
and all other persons in active concert or participation with any of them, who receive actual
notice of this Order, whether acting directly or indirectly, in connection with the manufacturing,
labeling, advertising, promotion, offering for sale, sale, or distribution of any Covered Product
are permanently restrained and enjoined from misrepresenting, in any manner, expressly or by
implication, including through the use of any product name, endorsement, depiction, or
illustration:
A.

That any Covered Product is scientifically proven to protect the brain against
Alzheimer’s disease or dementia, reverse memory loss, or improve memory,
concentration, or cognitive performance;

B.

That the performance or benefits of any Covered Product are scientifically or
clinically proven or otherwise established; or
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The existence, contents, validity, results, conclusions, or inteipretations o f any
test, study, or other research.
V.
FDA-APPROVED CLAIMS

IT IS FURTHER ORDERED that nothing in this Order prohibits Defendants,
Defendants’ officers, agents, employees, or all other persons in active concert or participation
with any of them from:
A.

For any drug, making a representation that is approved in labeling for such drug

under any tentative final or final monograph promulgated by the Food and Drug Administration,
or under any new drug application approved by the Food and Drug Administration; and
B.

For any product, making a representation that is specifically authorized for use in

labeling for such product by regulations promulgated by the Food and Drug Administration
pursuant to the Nutrition Labeling and Education Act of 1990 or permitted under Sections 303=
304 of the Food and Drug Administration Modernization Act of 1997.
VI.
PRESERVATION OF RECORDS RELATING TO COM PETENT AND RELIABLE
HUMAN CLINICAL TESTS OR STUDIES
IT IS FURTHER ORDERED that, with regard to any human clinical test or study
(“test”) upon which Defendants rely to substantiate any claim covered by this Order, Defendants
shall secure and preserve all underlying or supporting data and documents generally accepted by
experts in the field as relevant to an assessment of the test, including:
A.

All protocols and protocol amendments, reports, articles, write-ups, or other
accounts of the results of the test, and drafts of such documents reviewed by the
test sponsor or any other person not employed by the research entity;
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All documents referring or relating to recruitment; randomization; instructions,
including oral instructions, to participants; and participant compliance;

C.

Documents sufficient to identify all test participants, including any participants
who did not complete the test, and all communications with any participants
relating to the test; all raw data collected from participants enrolled in the test,
including any participants who did not complete the test; source documents for
such data; any data dictionaries; and any case report forms;

D.

All documents referring or relating to any statistical analysis of any test data,
including any pretest analysis, intent-to-treat analysis, or between-group analysis
performed on any test data; and

E.

All documents referring or relating to the sponsorship o f the test, including all
communications and contracts between any sponsor and the test’s researchers.

Provided' however, the preceding preservation requirement does not apply to a reliably
reported test, unless the test was conducted, controlled, or sponsored, in whole or in part by: (1)
any Defendant; (2) any Defendant’s officers, agents, representatives, or employees; (3) any other
person or entity in active concert or participation with any Defendant; (4) any person or entity
affiliated with or acting on behalf of any Defendant; (5) any supplier of any ingredient contained
in the product at issue to any of the foregoing or to the product’s manufacturer; or (6) the
supplier or manufacturer of such product.
For purposes of this Section, “reliably reported test” means a report of the test has been
published in a peer-reviewed journal, and such published report provides sufficient information
about the test for experts in the relevant field to assess the reliability of the results.
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For any test conducted, controlled, or sponsored, in whole or in part, by Defendants,
Defendants must establish and maintain reasonable procedures to protect the confidentiality,
security, and integrity of any personal information collected from or about participants. These
procedures must be documented in writing and must contain administrative, technical, and
physical safeguards appropriate to Corporate Defendant’s size and complexity, the nature and
scope of Defendants’ activities, and the sensitivity of the personal information collected from or
about the participants.
VII,
PROHIBITED REPRESENTATIONS
RELATED TO ENDORSEMENTS
IT IS FURTHER ORDERED that Defendants, Defendants’ officers, agents, employees,
and all other persons in active concert or participation with any of them, who receive actual
notice of this Order, whether acting directly or indirectly, in connection with the manufacturing,
labeling, advertising, promotion, offering for sale, sale, or distribution of any Covered Product,
are permanently restrained and enjoined from misrepresenting, in any manner, expressly or by
implication, including through the use of any good or service name, endorsement, depiction, or
illustration, that:
A.

Any person is an expert with respect to the endorsement message provided by
that person;

B.

Purported consumers who appear in advertising obtained a reported result through
use of those goods or services; and

C.

Experts are providing their objective, independent opinions regarding the efficacy
of any good or service.

Case 2:17-cv-00467-JDL Document 15 Filed 01/16/18 Page 14 of 33

PagelD #: 151

VIII,
O TH ER PROHIBITED MISREPRESENTATIONS
IT IS FURTHER ORDERED that Defendants, Defendants’ officers, agents, employees,
and all other persons in active concert or participation with any of them, who receive actual
notice of this Order, whether acting directly or indirectly, in connection with the advertising,
marketing, promotion, offering for sale, sale, or distribution of any good or service, are
permanently restrained and enjoined from misrepresenting, or assisting others in
misrepresenting, expressly or by implication:
A.

That consumers are receiving a money-back guarantee, a free trial offer, a risk
free trial offer, a free gift, or a bonus;

B.

The total cost to purchase, receive, or use the good or service, including shipping,
handling, processing, and any additional financial obligations that may be
incurred as a result of accepting the free product, service, or offer;

C.

The timing or manner of any Charge or bill;

D.

Any material restrictions, limitations, or conditions to purchase, receive, or use
the good or service;

E.

Any material aspect of the performance, efficacy, nature, or central characteristics
of the good or service;

F.

To the extent applicable, that customs duties or taxes may be assessed by the
relevant taxing authority; and

G.

Any material aspect of the nature or terms of a refund, return, cancellation,
exchange, or repurchase policy for the good or service, including the deadline (by
date or frequency) by which the consumer must act.
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IX.
REQUIRED DISCLOSURES
IT IS FURTHER ORDERED that, in connection with the advertising, marketing,
promotion, offering for sale, sale, or distribution of any good or service, Defendants and their
officers, agents, employees, and all other persons in active concert or participation with any of
them who receive actual notice of this Order, whether acting directly or indirectly, are
permanently restrained and enjoined from:
A.

Failing to Clearly and Conspicuously disclose, or assisting others in failing to

Clearly and Conspicuously disclose, before consumers are asked to reveal billing information
such as account number or to consent to any purchase in connection with any claim that a good
or seivice is offered on a “free,” “risk-free,” “trial,” “no obligation,” “reduced,” discounted basis,
or words of similar import, the following material terms and conditions of any offer:
1.

In Close Proximity to such claim, the total cost to purchase, or receive, or
use any good or service that is the subject of the sales offer, including
shipping, handling, and processing;

2.

The amount, timing, and manner of payment of all fees, Charges, or other
amounts that a consumer will be Charged or billed, and any
additional financial obligations that may be incurred as a result of
accepting the free product, service, or offer; and

3.

The terms and conditions of any refund, cancellation, exchange, or
purchase policy or policies, including the specific steps and means by
which such requests must be submitted, and the telephone number, email
address, web address, or street address to which such requests must be
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directed, including the deadline (by date or frequency) by which the
consumer must act, and, if there is a policy of not making refunds,
cancellations, exchanges, or repurchases, a statement regarding this
policy; and
B.

Obtaining, or assisting others in obtaining, billing information such as account

number from a consumer for any transaction involving a good or service that includes a Negative
Option Feature, without first disclosing Clearly and Conspicuously, and in Close Proximity to
where a consumer provides billing information:
1.

The extent to which the consumer must take affirmative action(s) to avoid
any Charges: a) for the offered good or service, b) of an increased amount
after any trial or promotional period ends, and c) on a recurring basis;

2.

The total cost (or range of costs) the consumer will be Charged (including
shipping, handling, and processing), the date the initial Charge will be
submitted for payment, and, if applicable, the frequency of such Charges
unless the consumer timely takes affirmative steps to prevent or stop such
Charges;

3.

The deadline(s) (by date or frequency) by which the consumer must
affirmatively act in order to stop all recurring Charges, whether such
recurring charges are refundable and, if so, the terms and conditions of any
refund policy;

4.

The name of the seller or provider of the good or service and, if the name
of the seller or provider will not appear on billing statements, the billing
descriptor that will appear on such statements;
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5.

A description of the good or service;

6.

Any Charge or cost for which the consumer is responsible in connection
with the cancellation of an order or the return of a good; and

7.

The mechanism to stop any recurring Charges.

In addition, for any transaction involving a sale of a good or service to a consumer
through a Negative Option Feature, within 10 days after the date of the sale, Defendants must
send the consumer written confirmation of the transaction, either by email or first class mail,
according to the consumer's preference, which is identified as a written confirmation in the email
subject line or on the outside of the envelope. Such written confirmation must include Clear and
Conspicuous disclosure of all the information required by this Subsection IX.B(l)-(7) above, and
must specify the procedures by which consumers can cancel or obtain a refund if a refund is
offered.
X.
EXPRESS INFORMED CONSENT
IT IS FURTHER ORDERED that Defendants, Defendants' officers, agents,
employees, and all other persons in active concert or participation with any of them, who receive
actual notice of this Order, whether acting directly or indirectly, in connection with the
advertising, marketing, promotion, offering for sale, sale, or distribution of any good or service,
are permanently restrained and enjoined from using billing information to obtain payment from a
consumer, unless, prior to using such billing information to obtain payment, they obtain the
express informed consent of the consumer.
A.

For all written offers with a Negative Option Feature (including over the Internet

or other web-based applications or services), a consumer's express informed consent must be
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obtained, prior to Defendants’ obtaining any billing information from consumers, through a
check box, signature, or other substantially similar method, that consumers must affirmatively
select or sign to accept the Negative Option Feature. Immediately adjacent to such check box,
signature, or substantially similar method, Defendants must disclose all costs associated with the
Negative Option Feature, including shipping, handling, and processing, that the consumer is
agreeing to pay such costs, the length of any trial period, and the date by which consumers must
cancel to avoid being Charged. This disclosure must contain no additional information and must
be Clear and Conspicuous in relation to any other information provided on the page relating to
costs, risks, or obligations associated with any Negative Option Feature, including any terms
referring to “free,” “trial,” and “processing fee.”
B.

For all oral offers including a Negative Option Feature, Defendants must, in

addition to disclosing the information identified in the Section entitled Required Disclosures, and
prior to obtaining any billing information such as account number from a consumer, obtain
affirmative and unambiguous oral confirmation that the consumer:
1.

Consents to authorizing payment for any goods or services, including
shipping, handling, and processing;

2.

Understands that the transaction includes a Negative Option Feature; and

3.

Understands the specific affirmative steps the consumer must take to
prevent further Charges.

Defendants must maintain for 3 years from the date of each transaction an unedited voice
recording of the entire transaction, including the prescribed statements set out in the Section
entitled Required Disclosures. Each recording must be retrievable by date and by the
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consumer’s name, telephone number, or billing information and must be provided upon request
and without Charge to the consumer, the consumer’s bank, or any law enforcement entity.
XI.
PROHIBITIONS CONCERNING REFUNDS AND CANCELLATIONS
IT IS FURTHER ORDERED that Defendants, Defendants’ officers, agents, employees,
and all other persons in active concert or participation with any of them, who receive actual
notice of this Order, whether acting directly or indirectly, in connection with the advertising,
marketing, promotion, offering for sale, sale, or distribution of any good or service, are
permanently restrained and enjoined from:
A.

Failing to honor a refund, return, or cancellation request that complies with any

policy to make refunds or allow returns or cancellations; and
B.

Failing to provide a simple mechanism for a consumer to immediately stop any

recurring Charge for such good or service, at least one of which is as simple and easy to use as
the mechanism the consumer used to initiate the Charges.
1.

For consumers who entered into the agreement to purchase a good or
service including a Negative Option Feature over the Internet or through
other web-based applications or services, Defendants must provide a
mechanism for consumers to stop the recurring Charge over the internet or
through such other web-based application or service.

2.

For consumers who entered into the agreement to purchase a good or
service including a Negative Option Feature through an oral offer and
acceptance, Defendants must maintain a telephone number through which
the consumer can easily cancel the good or service, seek a refund for past
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Charges where such refund is offered, and immediately stop all further
Charges. Defendants must answer all calls to this telephone number
during normal business hours.
XII.
COMPLIANCE W ITH THE ELECTRONIC FUND TRANSFER ACT
IT IS FURTHER ORDERED that Defendants, Defendants’ officers, agents, employees,
and all other persons in active concert or participation with any of them, who receive actual
notice of this Order, whether acting directly or indirectly, in connection with the advertising,
marketing, promotion, offering for sale, sale, or distribution of any good or service, are
permanently restrained and enjoined, in connection with any person who purchases any good or
service subsequent to the date of this Order, and who uses a debit card or other means of
electronic fund transfer, from:
A.

Failing to obtain written authorization for Preauthorized Electronic Fund

Transfers from a consumer’s account before initiating any Preauthorized Electronic Fund
Transfer, as required by Section 907(a) of the Electronic Fund Transfer Act, 15 U.S.C. §
1693e(a), and Section 1005.10(b) of Regulation E, 12 C.F.R. § 1005.10(b), as more fully set out
in Section 1005.10 of the Consumer Financial Protection Bureau’s Official Staff Commentary to
Regulation E, 12 C.F.R. § 1005, Supp. I; and
B.

Failing to maintain procedures reasonably adapted to avoid an unintentional

failure to obtain written authorization for a Preauthorized Electronic Fund Transfer, as required
in Section 1005.10 of the Consumer Financial Protection Bureau’s Official Staff Commentary to
Regulation E, 12 C.F.R. § 1005, Supp. I.
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XIII.
MONETARY JUDGMENT AND CONSUMER REDRESS
IT IS FURTHER ORDERED that:
A.

Judgment in the amount of $3,700,514 is hereby entered in favor of the

Commission against Defendants, jointly and severally, as equitable monetary relief.
B.

Defendants are ordered to pay to the Commission $800,000. Defendants stipulate

that they have posted $450,000 into the escrow account of their undersigned counsel for no
purpose other than payment to the Commission. Defendants will remit the balance of $350,000
to the escrow account of their undersigned counsel prior to submission of this Order to the Court
for approval. The escrowed funds shall be paid to the Commission within 7 days of the Court’s
entry of this Order and shall be transferred in accordance with the wire transfer instructions
previously provided to counsel by a representative of the Commission.
C.

Upon satisfaction of the obligations described in Subsection B above, the

remainder of the judgment as to the Defendants shall be suspended subject to Subsections E and
F below.
D.

In the event of default of any obligation to make payments under this Order,

including, but not limited to, failure to pay $800,000 to the Commission pursuant to Section B,
above, interest shall accrue as computed pursuant to 28 U.S.C. § 1961(a) from the date of default
to the date of payment. In the event such default continues for 10 calendar days beyond the date
any payments are due, the entire judgment amount of $3,700,514 shall immediately become due
and payable,
E.

Plaintiffs’ agreement to the suspension of part of the judgment is expressly

premised upon the truthfulness, accuracy, and completeness of Defendants’ sworn financial
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statements and related documents (collectively, “financial representations”) submitted to
Plaintiffs, namely the following:
1.

the Financial Statement of Individual Defendant Kramer Duhon signed on

December 19, 2016, including the attachments (HRL003490-3504; HRL004034);
2.

the Financial Statement of Corporate Defendant Health Research

Laboratories, LLC, signed by Kramer Duhon, President, on December 18, 2016, including the
attachments (HRL003474-3489); and
3.

the additional documentation and information submitted by letter from

Defendants’ counsel Andrew Lustigman to Commission counsel Elizabeth Nach, dated
December 22, 2016; January 13, 2017; February 8, 2017; February 17, 2017; February 28, 2017;
March 31, 2017; and April 20, 2017; including all attachments thereto (bates-stamped
HRL003227-4894 and 117 un-stamped JP Morgan investment account statements).
F.

The suspension of the judgment will be lifted as to any Defendant if, upon motion

by either of Plaintiffs, the Court finds that such Defendant failed to disclose any material asset,
materially misstated the value of any asset, or made any other material misstatement or omission
in the financial representations identified in Subsection E above.
G.

If the suspension of the judgment is lifted, the judgment becomes immediately

due as to the Defendant or Defendants causing the suspension to be lifted in the amount specified
in Subsection A above (which the parties stipulate only for purposes of this Section represents
the consumer injury alleged in the Complaint), less any payment previously made pursuant to
this Section, plus interest computed from the date of entry of this Order.
H.

All money paid to the Commission pursuant to this Order may be deposited into a

fund administered by the Commission or its designee to be used for equitable relief, including

Case 2:17-cv-00467-JDL Document 15 Filed 01/16/18 Page 23 of 33

PagelD #: 160

consumer redress and any attendant expenses for the administration of any redress fund. If a
representative of the Commission decides that direct redress to consumers is wholly or partially
impracticable or money remains after redress is completed, the money shall be divided with the
State of Maine. Any money not transferred to the State of Maine or not used by the Commission
for equitable relief, including consumer information remedies, is to be deposited to the U.S.
Treasury as disgorgement. Defendants have no right to challenge any actions the Commission or
its representatives may take pursuant to this Subsection.
i.

All money paid to the State of Maine pursuant to this Order must be deposited

into the Attorney General's other special revenue account and used for consumer education,
consumer protection, antitrust enforcement, or for any lawful purpose at the sole discretion of the
Attorney General.
J.

Defendants relinquish dominion and all legal and equitable right, title, and interest

in all assets transferred pursuant to this Order and may not seek the return of any assets.
K.

The facts alleged in the Complaint will be taken as true, without further proof, in

any subsequent civil litigation by or on behalf of either of Plaintiffs, in a proceeding to enforce
their rights to any payment or monetary judgment pursuant to this Order, such as a
nondischargeabiiity complaint in any bankruptcy case.
L.

The facts alleged in the Complaint establish all elements necessary to sustain an

action by either of Plaintiffs pursuant to Section 523(a)(2)(A) of the Bankruptcy Code, 11 U.S.C,
§ 523(a)(2)(A), and this Order will have collateral estoppel effect for such purposes.
M.

Defendants acknowledge that their Taxpayer Identification Numbers (Social

Security Numbers or Employer Identification Numbers), which Defendants previously submitted

Case 2:17-cv-00467-JDL Document 15 Filed 01/18/18 Page 24 of 33

PagelD #: 161

to Plaintiffs, may be used for collecting and reporting on any delinquent amount arising out of
this Order, in accordance with 31 U.S.C. § 7701.
XIV.
COOPERATION W ITH FTC AND MAINE
IT IS FURTHER ORDERED that Defendants must fully cooperate with representatives
of the Commission, the Maine AG, and any of their representatives in this case and in any
investigation related to or associated with the transactions or the occurrences that are the subject
of the Complaint. Defendants must provide truthful and complete information, evidence, and
testimony. Individual Defendant must appear and Corporate Defendant must cause its officers,
employees, representatives, or agents to appear for interviews, discovery, hearings, trials, and
any other proceedings that a representative of the Commission or the Maine AG may reasonably
request upon 5 days' written notice, or other reasonable notice, at such places and times as a
Commission or Maine AG representative may designate, without the service of a subpoena.
Defendants may have counsel present.
XV.
CUSTOM ER INFORM ATION
IT IS FURTHER ORDERED that Defendants’ officers, agents, and employees, and ail
other persons in active concert or participation with any of them, who receive actual notice of
this Order, are permanently restrained and enjoined from directly or indirectly:
A.

Failing to provide sufficient customer information to enable the Commission to

efficiently administer consumer redress. If a representative of the Commission requests in
writing any information related to redress, Defendants must provide it, in the form prescribed by
the Commission, within 14 days.
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Disclosing, using, or benefitting from customer information, including the name,

address, telephone number, email address, Social Security number, other identifying information,
or any data that enables access to a customer’s account (including a credit card, bank account, or
other financial account), that any Defendant obtained prior to entry of this Order in connection
with the labeling, advertising, marketing, distribution, or sale of any formulation of BioTherapex
or NeuroPlus; and
C.

Failing to destroy such customer information in all forms in their possession,

custody, or control within 30 days after receipt of written direction to do so from representatives
of both the Commission and the Maine AG.
Provided\ however, that customer information need not be destroyed, and may be
disclosed, to the extent requested by a government agency or required by law, regulation, or
court order.
XVI.
ORDER ACKNOWLEDGMENTS
IT IS FURTHER ORDERED that Defendants obtain acknowledgments of receipt of
this Order:
A.

Each Defendant, within 7 days of entry of this Order, must submit to the

Commission and the Maine AG an acknowledgment of receipt of this Order sworn under penalty
of perjury.
B.

For 10 years after entry of this Order, the Individual Defendant for any business

involved in the sale or marketing of any Covered Product that such Defendant, individually or
collectively with the Corporate Defendant, is the majority owner or controls directly or
indirectly, and the Corporate Defendant, must deliver a copy of this Order to:
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1.

All principals, officers, directors, and LLC managers and members;

2.

All employees, agents, and representatives with managerial responsibility
who participate in the manufacturing, labeling, advertising, marketing,
distribution, or sale o f any Covered Product or service; and

3.

Any business entity resulting from any change in structure as set forth in
the Section titled Compliance Reporting.

Delivery must occur within 7 days of entry of this Order for current personnel. For all others,
delivery must occur before they assume their responsibilities.
C.

From each individual or entity to which a Defendant delivered a copy of this

Order, that Defendant must obtain, within 30 days, a signed and dated acknowledgment of
receipt of this Order.
XVII.
COMPLIANCE REPORTING
IT IS FURTHER ORDERED that Defendants make timely submissions to the
Commission and to the Maine AG:
A.

Sixty days after entry of this Order, each Defendant must submit a compliance

report, sworn under penalty of perjury:
1.

Each Defendant must: (a) identify the primary physical, postal, and email
address and telephone number as designated points of contact, which
Plaintiffs’ representatives may use to communicate with Defendant;
(b) identify all of that Defendant’s businesses by all of their names,
telephone numbers, and physical, postal, email, and Internet addresses;
(c) describe the activities of each business, including the goods and
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services offered, the means of advertising, marketing, and sales, and the
involvement of the other Defendant (which Individual Defendant must
describe if he knows or should know due to his own involvement);
(d) describe in detail whether and how that Defendant is in compliance
with each Section o f this Order; and (e) provide a copy of each
Order Acknowledgment obtained pursuant to this Order, unless
previously submitted to Plaintiffs.
2.

Additionally, the Individual Defendant must: (a) identify all telephone
numbers and all physical, postal, email, and Internet addresses, including
all residences; (b) identify all business activities, including any business
for which such Defendant performs services whether as an employee or
otherwise and any entity in which such Defendant has any ownership
interest; and (c) describe in detail such Defendant’s involvement in each
such business, including title, role, responsibilities, participation,
authority, control, and any ownership.

B.

For 10 years after entry of this Order, each Defendant must submit a compliance

notice, sworn under penalty of perjury, within 14 days o f any change in the following:
1.

Each Defendant must report any change in: (a) any designated point of
contact; (b) the structure of the Corporate Defendant or any entity that
Defendants have any ownership interest in or control directly or indirectly
that may affect compliance obligations arising under this Order,
including: creation, merger, sale, or dissolution of the entity or any
subsidiary, parent, or affiliate that engages in any acts or practices subject
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to this Order,
2.

Additionally, the Individual Defendant must report any change in:
(a) names, including aliases or fictitious names, or residence addresses; or
(b) titles or roles in any business activity, including any business for which
such Defendant performs services whether as an employee or otherwise
and any entity in which such Defendant has any ownership interest, and
identify the name, physical address, and any Internet address of the
business or entity.

C.

For a period of 20 years, each Defendant must submit to the Commission and the

Maine AG notice of the filing of any bankruptcy petition, insolvency proceeding, or similar
proceeding by or against such Defendant within 14 days of its filing.
D.

Any submission to the Commission or the Maine AG required by this Order to be

sworn under penalty of perjury must be true and accurate and comply with 28 U.S.C. § 1746,
such as by concluding: “1 declare under penalty of perjury under the laws of the United States of
America that the foregoing is true and correct. Executed on: ________ ” and supplying the date,
signatory’s full name, title (if applicable), and signature.
E.

Unless otherwise directed by a Commission representative in writing, all

submissions to the Commission pursuant to this Order must be emailed to DEBrief@ftc.gov or
sent by overnight courier (not the U.S. Postal Service) to: Associate Director for Enforcement,
Bureau of Consumer Protection, Federal Trade Commission, 600 Pennsylvania Avenue, N.W.,
Washington, D.C. 20580. The subject line must begin: FTC v. Health Research Laboratories,
LLC, e ta l, and the number X I80007.
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Unless otherwise directed by a Maine AG representative in writing, all

submissions to the Maine AG pursuant to this Order must be sent by overnight courier (not the
U.S. Postal Service) to: Office of the Attorney General of Maine, Consumer Protection Division,
111 Sewall Street, 6th Floor, Augusta, ME 04330. The subject line must begin: Order in re
State o f Maine v. Health Research Laboratories, LLC, et at, and must identify the Court and
docket number of this Order as ordered by the Court.
XVIII,
RECORDKEEPING
IT IS FURTHER ORDERED that in connection with the sale of any Covered Product,
Defendants must create certain records for 10 years after entry of the Order, and retain each such
record for 8 years. Specifically, the Corporate Defendant and the Individual Defendant for any
business that such Defendants, individually or collectively, is a majority owner or controls
directly or indirectly, must create and retain the following records:
A.

Accounting records showing the revenues from all goods or services sold, all

costs incurred in generating those revenues, and the resulting net profit or loss;
B.

Personnel records showing, for each person providing services, whether as an

employee or otherwise, that person’s: name; address; telephone numbers; job title or position;
dates of service; and (if applicable) the reason for termination;
C.

Complaints and full or partial refund requests, whether received directly or

indirectly, such as through a third party, and any response;
D.

All records necessary to demonstrate full compliance with each provision of this

Order, including all submissions to the Commission and the Maine AG; and
E.

A copy of each unique advertisement or other marketing material.
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XIX.
COMPLIANCE MONITORING
IT IS FURTHER ORDERED that, for the purpose of monitoring Defendants’
compliance with this Order:
A.

Within 14 days of receipt of a written request from a representative of the

Commission or the Maine AG, each Defendant must: submit additional compliance reports or
other requested information, which must be sworn under penalty of perjury; appear for
depositions; and produce documents for inspection and copying. Plaintiffs are also authorized to
obtain discovery, without further leave of court, using any of the procedures prescribed by
Federal Rules of Civil Procedure 29, 30 (including telephonic depositions), 31, 33, 34, 36, 45,
and 69.
B.

For matters concerning this Order, Plaintiffs are authorized to communicate

directly with each Defendant. Defendants must permit Plaintiffs’ representatives to interview
any employee or other person affiliated with any Defendant who has agreed to such an interview.
The person interviewed may have counsel present.
C.

Plaintiffs may use all other lawful means, including posing, through their

representatives, as consumers, suppliers, or other individuals or entities, to Defendants or any
individual or entity affiliated with Defendants, without the necessity of identification or prior
notice. Nothing in this Order limits the Commission’s lawful use of compulsory process,
pursuant to Sections 9 and 20 of the FTC Act, 15U.S.C, §§49, 57b-l. Nothing in this Order
limits the Maine AG’s lawful use of compulsory process, pursuant to section 211 of the Maine
UTPA, 5 M.R.S.A. §211. Defendants hereby consent to the disclosure by the Maine AG to any
law enforcement agency and any representative of the State of Maine of any material or
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information produced by Defendants pursuant to section 211 of the Maine UTPA, whether
produced before or after the date of this Order.
D.

Upon written request from a representative of the Commission or the Maine AG,

any consumer reporting agency must furnish consumer reports concerning Individual Defendant,
pursuant to Section 604(1) of the Fair Credit Reporting Act, 15 U.S.C. § 1681b(a)(l).
XX.
RETENTION OF JURISDICTION
IT IS FURTHER ORDERED that this Court shall retain jurisdiction of this matter for
purposes of construction, modification, and enforcement of this Order.
IT IS SO ORDERED this 16th day of January, 2018.

1st Jon D. Levy
U.S. DISTRICT JUDGE
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IT IS SO STIPULATED this 30th day of November, 2017.
DAVID C. SHONKA
Acting General Counsel
/s/ Elizabeth K. Nach
Elizabeth K. Nach
James A. Prunty
Federal Trade Commission
600 Pennsylvania Avenue, NW
Washington, D.C. 20580
Telephone: 202-326-2611, -2438
Facsimile: 202-326-3259
Email: enach@ftc.gov, jprunty@ftc.gov
Attorneys for Plaintiff
FEDERAL TRADE COMMISSION

IT IS SO STIPULATED this 30th day of November, 2017.

JANET T. MILLS
Attorney General, State of Maine
/s/ Brendan F.X. O'Neil
Brendan F.X. O'Neil
Linda J. Conti
Assistant Attorney General
Office of the Attorney General of Maine
6 State House Station
Augusta, Maine 04333-0006
Telephone: 207-626-8842, -8591
Facsimile: 207-624-7730
Email: brendan.oneil@maine.gov
linda.conti@maine.gov
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IT IS SO STIPULATED this 30th day of November, 2017.

HEALTH RESEARCH LABORATORIES, LLC
By:
/s/ Kramer Duhon
KRAMER DUHON, individually, and as an owner
and officer of HEALTH RESEARCH
LABORATORIES, LLC

IT IS SO STIPULATED this 30th day of November, 2017.

ATTORNEYS FOR DEFENDANTS HEALTH
RESEARCH LABORATORIES, LLC AND
KRAMER DUHON
/s/ Andrew B. Lustigman
Andrew B. Lustigman, Esq.
Olshan Frame Wolosky LLP
1325 Avenue of the Americas
New York, NY 10019
Telephone: (212) 451-2258
Facsimile: (212)451-2222
Email: aIustigman@olshanlaw.com
Pro hac vice forthcoming
/s/ David J. Marche se
Appearing on behalf of Defendants
Health Research Laboratories, LLC and
Kramer Duhon
David J. Marchese, Esq.
Drummond & Drummond, LLP
1 Monument Way
Portland, ME 04101
Telephone: 207-774-0317
Email: dmarchese@ddlaw.com

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MAINE

FEDERAL TRADE COMMISSION and
STATE of MAINE,

Case No. 2:17-cv-00467-JDL

Plaintiffs,
-v.HEALTH RESEARCH LABORATORIES, LLC,
a limited liability company, and
KRAMER DUHON, individually and as an owner
and officer of HEALTH RESEARCH
LABORATORIES, LLC,
Defendants.

STATEMENT OF COMPLIANCE
I,

Kramer Duhon, on behalf of myself and Health Research Laboratories, LLC

(hereinafter, “LLC”), do hereby state as follows:
1.

I have received a copy o f the Stipulated Final Judgment And Order For

Permanent Injunction And Other Equitable Relief that was filed and entered by the Court on or
about January 16,2018 (hereinafter, “the Order”).
2.

I further acknowledge that I have delivered or caused to be delivered a copy of the

Order to all principals, officers, directors, and LLC managers and members and to all employees,
agents and representatives with managerial responsibility who participate in the manufacturing,
labeling, advertising, marketing, distribution, or sale of BioTherapex and NeuroPlus.
3.

It is my understanding that complete full payment of $800,000.00 has now been

made to the Federal Trade Commission pursuant to Section XIII.B of the Order.

4.

Pursuant to 28 U.S.C. § 1746,1 declare under penalty of perjury under the laws of

the United States of America that the foregoing is true and correct to the best of my knowledge
and information.
Executed on January 23, 2018

